- NCIt
- C40078
Loading cancer entity…
Loading cancer entity…
Variants & evidence
2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ARID1A Loss1 | |||||||
| (oncogenic) | Oncogenic | B | Supports Oncogenicity | 4 | submitted | EID13135Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC) PMID 20942669 · Wiegand et al., 2010 · Open in CIViC | civic |
| PIK3CA Activation mutation1 | |||||||
| (oncogenic) | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID13136Ovarian clear cell carcinoma is an aggressive and relatively chemotherapy-resistant form of ovarian cancer with a molecular landscape distinct from that of the more common epithelial subtypes. Earlier… (full text at CIViC) PMID 19349352 · Kuo et al., 2009 · Open in CIViC | civic |
Data updated 20 minutes agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.